Eris Lifesciences Limited — Board Meeting, 04-02-2025: Outcome of Board Meeting

The Board of Directors of Eris Lifesciences Limited has approved the unaudited financial results for the quarter and nine months ended December 31, 2024. For the quarter, total revenue reached ₹727.45 crore, with a net profit of ₹86.93 crore. The results reflect an increase due to recent acquisitions, including the Nephrology and Dermatology business and Swiss Parenterals Limited, which impacted comparability with prior periods. The company's current paid-up equity share capital stands at ₹13.61 crore after issuing shares under employee stock options. The management is also progressing towards finalizing the details of these acquisitions.